Kramer W G, Cleary T, Frankel L S, Kohl S, Pickering L K
Clin Pharmacol Ther. 1979 Nov;26(5):635-40. doi: 10.1002/cpt1979265635.
Amikacin kinetics was studied in 8 pediatric oncology patients who received the drug by intravenous infusion over 30 or 60 min at a dose of 5 mg/kg every 6 or 8 hr. This regimen is recommended but, due to patient variability, patients should be monitored. Dosing intervals during 1 or 2 and 3 or 4 days of therapy were studied with serum samples collected before and at the end of the infusion and serially to the end of the dosing interval. The data appeared consistent with and were analyzed according to 1-compartment model. An equation describing serum concentration with time for the multiple-dose case was fit to each patient's multiple-interval data with nonlinear regression. Half-life averaged 1.2 hr. volume of distribution 0.24 l/kg, and total body clearance 109 ml/min/1.73 m2 or 2.51 ml/min/kg. The volume of distribution and the clearance are greater than reported for adults and probably account for the larger dose needed to achieve and maintain therapeutic levels. Although the total daily dose was greater than previously reported, there were no signs of toxicity, although therapuetic concentrations were maintained.
对8名儿科肿瘤患者的阿米卡星动力学进行了研究，这些患者以每6或8小时5mg/kg的剂量在30或60分钟内静脉输注该药物。这种给药方案是推荐的，但由于患者个体差异，应对患者进行监测。在治疗的第1或2天以及第3或4天的给药间隔期间进行了研究，在输注前、输注结束时以及直至给药间隔结束时连续采集血清样本。数据似乎符合一室模型并据此进行分析。用非线性回归将描述多剂量情况下血清浓度随时间变化的方程拟合到每位患者的多个间隔数据。半衰期平均为1.2小时，分布容积为0.24l/kg，全身清除率为109ml/min/1.73m²或2.51ml/min/kg。分布容积和清除率均高于成人报道的值，这可能是达到和维持治疗水平所需较大剂量的原因。尽管每日总剂量高于先前报道，但尽管维持了治疗浓度，但未出现毒性迹象。
